Health & Fitness
Tue, September 15, 2009Mon, September 14, 2009Fri, September 11, 2009Thu, September 10, 2009Wed, September 9, 2009Tue, September 8, 2009Sun, September 6, 2009Fri, September 4, 2009Thu, September 3, 2009Wed, September 2, 2009Tue, September 1, 2009Mon, August 31, 2009Fri, August 28, 2009Thu, August 27, 2009Wed, August 26, 2009Tue, August 25, 2009Mon, August 24, 2009Sun, August 23, 2009Fri, August 21, 2009Thu, August 20, 2009Wed, August 19, 2009Tue, August 18, 2009Mon, August 17, 2009Sun, August 16, 2009Fri, August 14, 2009Thu, August 13, 2009Wed, August 12, 2009Tue, August 11, 2009Mon, August 10, 2009Fri, August 7, 2009Thu, August 6, 2009Wed, August 5, 2009Tue, August 4, 2009Mon, August 3, 2009Sat, August 1, 2009Fri, July 31, 2009Thu, July 30, 2009Wed, July 29, 2009Tue, July 28, 2009Mon, July 27, 2009Sat, July 25, 2009Fri, July 24, 2009Thu, July 23, 2009Wed, July 22, 2009Daxor Corp.: Daxor Announces Third Quarter Dividend
Published in Health and Fitness on Monday, August 17th 2009 at 5:49 GMT, Last Modified on 2009-08-17 05:49:20 by Market Wire
NEW YORK, NY--(Marketwire - August 17, 2009) - Daxor Corporation (
This is the second dividend the Company has declared for 2009. The Company paid a dividend of $0.10 per share on Monday, June 15, 2009.
These payments are in keeping with the declaration of Company management in 2008 to pay dividends when funds are available.
For the year ended December 31, 2008, the Company paid a total dividend of $1.50 per share as follows: $0.25 per share on August 26th and November 26th and a special dividend of $1.00 per share on December 30, 2008.
As part of our ongoing research and development efforts, Daxor was actively engaged in participating in several clinical trials in three strategic areas: Intensive Critical Care Medicine, Heart Failure/Hypertension and Dialysis. Of the five current clinical trials, one has recently been completed, Blood Volume Analysis in treating ICU Patients - A Prospective, Randomized Outcome Study. The basis of this study was to investigate if the inclusion of a measured blood volume analysis from Daxor's BVA-100 would result in (1) a change in treatment; (2) improved clinical outcomes; and (3) reductions in the cost of care.
Daxor is also coordinating its first multi-center, prospective, blinded outcome study in heart failure. The TEAM HF (Treatment to Euvolemia by Assessment and Measured Blood Volume in Heart Failure) will be comprised of nine (9) medical centers and a total of 300 patients. This study will investigate if utilizing a measured blood volume while treating heart failure patients following a hospital stay will decrease a patient's need to revisit the hospital, decrease the mortality rate and improve their overall treatment and quality of life while living with heart failure.
Daxor Corporation manufactures and markets the BVA-100, the only FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website [ www.Daxor.com ].
